[1]
Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol., 2016, 131(6), 803-820.
[2]
Ostrom, Q. T.; Gittleman, H.; Liao, P.; Vecchione-Koval, T.; Wolinsky, Y.; Kruchko, C.; Barnholtz-Sloan, J. S. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro. Oncol., 2017, 19((suppl_5)), v1-v88.
[3]
Ohgaki, H.; Kleihues, P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol., 2005, 64(6), 479-489.
[4]
Zhong, J.; Paul, A.; Kellie, S.J.; O’Neill, G.M. Mesenchymal migration as a therapeutic target in glioblastoma. J. Oncol., 2010, 2010, 1-17.
[5]
Wen, P.Y.; Macdonald, D.R.; Reardon, D.A.; Cloughesy, T.F.; Sorensen, A.G.; Galanis, E.; DeGroot, J.; Wick, W.; Gilbert, M.R.; Lassman, A.B. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol., 2010, 28(11), 1963-1972.
[6]
Wong, T.Z.; van der Westhuizen, G.J.; Coleman, R.E. Positron emission tomography imaging of brain tumors. Neuroimaging Clin. N. Am., 2002, 12(4), 615-626.
[7]
Macdonald, D.R.; Cascino, T.L.; Schold, S.C.; Cairncross, J.G. Response criteria for phase ii studies of supratentorial malignant glioma. J. Clin. Oncol., 1990, 8(7), 1277-1280.
[8]
Ricci, P.E.; Karis, J.P.; Heiserman, J.E.; Fram, E.K.; Bice, A.N.; Drayer, B.P. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am. J. Neuroradiol., 1998, 19(3), 407-413.
[9]
Yoshimoto, M.; Waki, A.; Obata, A.; Furukawa, T.; Yonekura, Y.; Fujibayashi, Y. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl. Med. Biol., 2004, 31(7), 859-865.
[10]
Utriainen, M.; Komu, M.; Vuorinen, V.; Lehikoinen, P.; Sonninen, P.; Kurki, T.; Utriainen, T.; Roivainen, A.; Kalimo, H.; Minn, H. Evaluation of brain tumor metabolism with [11C]Choline PET and 1H-MRS. J. Neurooncol., 2003, 62(3), 329-338.
[11]
Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352(10), 987-996.
[12]
Kaur, G.; Bloch, O.; Jian, B.J.; Kaur, R.; Sughrue, M.E.; Aghi, M.K.; McDermott, M.W.; Berger, M.S.; Chang, S.M.; Parsa, A.T. A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. J. Neurosurg., 2011, 115(4), 754-759.
[13]
Heit, J.J.; Iv, M.; Wintermark, M. Imaging of intracranial hemorrhage. J. Stroke, 2017, 19(1), 11-27.
[14]
Kidwell, C.S.; Wintermark, M. Imaging of intracranial haemorrhage. Lancet Neurol., 2008, 7(3), 256-267.
[15]
Brandsma, D.; Stalpers, L.; Taal, W.; Sminia, P.; van den Bent, M.J. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol., 2008, 9(5), 453-461.
[16]
Ullrich, R.; Backes, H.; Li, H.; Kracht, L.; Miletic, H.; Kesper, K.; Neumaier, B.; Heiss, W-D.; Wienhard, K.; Jacobs, A.H. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-l-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin. Cancer Res., 2008, 14(7), 2049-2055.
[17]
Falk Delgado, A.; Falk Delgado, A. Discrimination between primary low-grade and high-grade glioma with 11C-methionine PET: A bivariate diagnostic Test accuracy meta-analysis. Br. J. Radiol., 2018, 91(1082), 20170426.
[18]
Kits, A.; Martin, H.; Sanchez-Crespo, A.; Delgado, A.F. Diagnostic accuracy of 11C-methionine PET in detecting neuropathologically confirmed recurrent brain tumor after radiation therapy. Ann. Nucl. Med., 2018, 32(2), 132-141.
[19]
Pauleit, D.; Stoffels, G.; Bachofner, A.; Floeth, F.W.; Sabel, M.; Herzog, H.; Tellmann, L.; Jansen, P.; Reifenberger, G.; Hamacher, K. et al. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl. Med. Biol., 2009, 36(7), 779-787.
[20]
Galldiks, N.; Rapp, M.; Stoffels, G.; Fink, G.R.; Shah, N.J.; Coenen, H.H.; Sabel, M.; Langen, K-J. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]fluoroethyl-l-tyrosine PET in comparison to MRI. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40(1), 22-33.
[21]
Chen, W.; Silverman, D.H.S.; Delaloye, S.; Czernin, J.; Kamdar, N.; Pope, W.; Satyamurthy, N.; Schiepers, C.; Cloughesy, T. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J. Nucl. Med., 2006, 47(6), 904-911.
[22]
Ramírez de Molina, A.; Rodríguez-González, A.; Gutiérrez, R.; Martínez-Piñeiro, L.; Sánchez, J.; Bonilla, F.; Rosell, R.; Lacal, J. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem. Biophys. Res. Commun., 2002, 296(3), 580-583.
[23]
Kotzerke, J.; Prang, J.; Neumaier, B.; Volkmer, B.; Guhlmann, A.; Kleinschmidt, K.; Hautmann, R.; Reske, S.N. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur. J. Nucl. Med., 2000, 27(9), 1415-1419.
[24]
Ohtani, T.; Kurihara, H.; Ishiuchi, S.; Saito, N.; Oriuchi, N.; Inoue, T.; Sasaki, T. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur. J. Nucl. Med., 2001, 28(11), 1664-1670.
[25]
Kobori, O.; Kirihara, Y.; Kosaka, N.; Hara, T. Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer, 1999, 86(9), 1638-1648.
[26]
Hara, T.; Inagaki, K.; Kosaka, N.; Morita, T. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J. Nucl. Med., 2000, 41(9), 1507-1513.
[27]
Tian, M.; Zhang, H.; Oriuchi, N.; Higuchi, T.; Endo, K. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(8), 1064-1072.
[28]
Hara, T. 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol. Imaging Biol., 2002, 4(4), 267-273.
[29]
Hara, T.; Kondo, T.; Hara, T.; Kosaka, N. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J. Neurosurg., 2003, 99(3), 474-479.
[30]
DeGrado, T.R.; Baldwin, S.W.; Wang, S.; Orr, M.D.; Liao, R.P.; Friedman, H.S.; Reiman, R.; Price, D.T.; Coleman, R.E. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J. Nucl. Med., 2001, 42(12), 1805-1814.
[31]
DeGrado, T.R.; Reiman, R.E.; Price, D.T.; Wang, S.; Coleman, R.E. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J. Nucl. Med., 2002, 43(1), 92-96.
[32]
Parashar, B.; Wernicke, A.G.; Rice, S.; Osborne, J.; Singh, P.; Nori, D.; Vallabhajosula, S.; Goldsmith, S.; Chao, K.S.C. Early assessment of radiation response using a novel functional imaging modality -- [18F]fluorocholine PET (FCH-PET): a pilot study. Discov. Med., 2012, 14(74), 13-20.
[33]
Liu, D.; Hutchinson, O.C.; Osman, S.; Price, P.; Workman, P.; Aboagye, E.O. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br. J. Cancer, 2002, 87(7), 783-789.
[34]
Glunde, K.; Jie, C.; Bhujwalla, Z.M. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res., 2004, 64(12), 4270-4276.
[35]
Glunde, K.; Jacobs, M.A.; Bhujwalla, Z.M. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev. Mol. Diagn., 2006, 6(6), 821-829.
44
2
1
1